0H7R.L
Abeona Therapeutics Inc
Q2 2025 Report
Abeona Therapeutics Inc (0H7R.L) QQ2 2025 Financial Results – USD...
Read full report
Executive Summary
Abeona Therapeutics’ QQ1 2025 results reflect a non-revenue quarter dominated by ongoing R&D investments and a substantial operating loss, consistent with a clinical-stage biotech profile. Revenue remained nil, with a gross loss of $0.815 million and a cumulative operating loss of $19.727 million. After including total other income of $7.698 million, the company reported a net loss of $12.029 million and basic earnings per share of -$0.24. The quarterly EBITDA stood at -$10.216 million, underscoring the heavy R&D burn that funds late-stage programs and early-stage AAV-era investments. YoY improvements in net income (up 61.9%) contrast with a QoQ deterioration in profitability, driven largely by the absence of near-term revenue and persistent operating expenses.
Key Performance Indicators
Operating Income
-19.73M
QoQ: -18.32% | YoY:-37.66%
Net Income
-12.03M
QoQ: -29.44% | YoY:61.91%
EPS
-0.24
QoQ: -4.35% | YoY:79.31%
Revenue Trend
Margin Analysis
Key Insights
Revenue: None reported for QQ1 2025 (Q1). Gross Profit: -$0.815 million (Gross Margin -N/A); YoY change -12.57%, QoQ change -134.09%. Operating Income: -$19.727 million; YoY -37.66%, QoQ -18.32%. Net Income: -$12.029 million; YoY +61.91%, QoQ -29.44%. EBITDA: -$10.216 million. Earnings per Share (EPS): -$0.24; YoY +79.31%, QoQ -4.35%. Cash Flow: Net cash from operating activities -$18.402 million; Free cash flow -$19.803 million. Balance sheet highlights show substantial liquidity (cash and shor...